May 2015 May 2015
New Product - Arzerra
Arzerra (ofatumumab (rmc)) is a human monoclonal antibody (IgG1ĸ) that binds specifically to both the small and large extracellular loops of the CD20 molecule epitopes on the human CD20 molecule on B cells. The binding of ofatumumab to the membrane proximal epitope of the CD20 molecule induces recruitment and activation of the complement pathway at the cell surface, leading to complement dependent cytotoxicity and resultant lysis of tumour cells. In addition, the binding of ofatumumab induces cell death through antibody dependent cell mediated cytotoxicity. Arzerra is indicated in combination with chlorambucil or bendamustine, for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and are inappropriate for fludarabine-based therapy. Arzerra as a single agent is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) refractory to fludarabine and alemtuzumab. Arzerra is available as a 100 mg/5 ml vial concentrate for infusion in packs of 3’s and 1000 mg/50 ml vial in packs of 1’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au